Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Promising RNAi Developments Boost Silence Therapeutics' Buy Rating
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Chardan Capital Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $55
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Buy Rating for Silence Therapeutics: Promising Phase 1 Results and Future Prospects
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49
Jefferies Initiates Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $40
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
Morgan Stanley Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $49